Oslo Cancer Cluster

28/01/2026

📸 Cancer Crosslinks 2026 — in pictures!

Cancer Crosslinks turns 18 in 2026 — one of Norway’s longest-running cancer research meeting series. This year’s conference brought together world-leading experts, clinicians and researchers to Oslo Cancer Cluster Innovation Park on 22 January, with over 200 participants attending the educational sessions in person.

From precision cancer medicine and AI in pathology, to deep genome sequencing and novel theranostics, the programme showcased cutting-edge science and translational insights that are shaping the future of oncology.

We’ve published a picture show highlighting the energy, discussions and collaborations from the day — featuring keynote talks, full auditoriums and networking moments that reflect the vibrancy of our oncology community. Recordings of the sessions will be shared soon on the event website.

Cancer Crosslinks turns 18 years in 2026, making it one of the best-established cancer meeting series in Norway. This is what it looks like.

13/01/2026

Get to know the leading scientists and clinicians taking the stage at the new edition of Cancer Crosslinks, on 22 January. The event is free of charge, both on-site and digitally.

Get to know the leading scientists and clinicians taking the stage at the new edition of Cancer Crosslinks on 22 January. And sign up to join us for free!

05/01/2026

En ny film tar oss med gjennom mer enn hundre år med norsk kreftforskning og behandling. Den viser hvordan et pionérmiljø vokste frem – og hvordan dagens Campus Radiumhospitalet bygger videre på denne arven i møte med fremtidens pasientbehov. Filmen hadde verdenspremiere på 10-års jubileet ...

25/11/2025

Hvorfor ønsker sykehus, akademia og private selskaper å samarbeide mer om ny kreftbehandling? På Campus Radiumhospitalet har vi gjort samarbeidet mellom offentlige og private krefter til en bærebjelke for et helt nytt hus! Møt Tuva Holt Hereng fra Thermo Fisher Scientific og Kjetil Tasken fra Oslo universitetssykehus utenfor nye John Ugelstad Hus i Oslo Cancer Cluster Innovasjonspark, og få svar på hvorfor de samarbeider!

Vi møter Tuva Holt Hereng, Senior Manager R&D Cell Therapy i Thermo Fisher Scientific, og Kjetil Taskén, leder av Institutt for Kreftforskning, Oslo Universi...

24/11/2025

Considering applying for EU grants? A well-planned soft funding strategy can unleash your company's potential and help bring your idea to market faster. But where to start? And who to ask for advice? 💡

👀 For pro tips, read this story!

A well-planned soft funding strategy can unleash a company's potential and help bring its idea to market faster.

28/10/2025

Who are the three finalists for the Kreftforeningen (Norwegian Cancer Society) Innovation Prize? Read the story to find out!

The winner will be announced on 27 November at the 10th anniversary of Oslo Cancer Cluster Innovation Park. 🥳

Three finalists are shortlisted for the Norwegian Cancer Society Innovation Prize.

13/10/2025

👏 Big thanks to everyone who attended the Cell Therapy Innovation Symposium 2025!
Hosted by Thermo Fisher Scientific and Oslo Cancer Cluster in collaboration with the CellFit Project, the event was packed with scientists and industry leaders tackling the future of immune cell therapy manufacturing.

🔎 Missed the event? Read more here: https://oslocancercluster.no/news/advancing-cell-therapy-manufacturing

moderator: Tuva Holt Hereng & Else Marit Inderberg
Pictured from the left: Fredrik Schjesvold, Anna Pasetto, Manel Juan, Nathalie Belmonte, Ulrike Köhl, and Lamberto Torralba-Raga, Ph.D.

30/09/2025

I dag distribueres Mediaplanets årlige innstikk i Aftenposten om kreft. Vi fikk en sponset plass for fortelle om hvordan vi i Norges eldste helseklynge jobber for å gi kreftpasienter raskere og bedre behandling og diagnostikk. Du kan også lese intervjuet med Ketil Widerberg på nettstedet altomdinhelse.

Oslo Cancer Cluster, samlokalisert med Radiumhospitalet, er en klynge og en non-profit medlemsorganisasjon som bidrar til å finne rett behandling til riktig pasient og tid.

15/09/2025

In our ongoing awareness series, we are dedicated to raising awareness about blood cancer, including leukemia, lymphoma, and myeloma.

Today, we want to bring special attention to the innovative work being done in Norway:

💠Sigrid Skånland’s project group at Oslo universitetssykehus
This group focuses on functional precision medicine for blood cancers, with an emphasis on chronic lymphocytic leukemia (CLL). Their research aims to address challenges in treating CLL, like drug resistance, side effects, and relapse. While new therapies have helped, they are not a cure. The group believes there is a need to customize treatment for each patient.

💠CellFit Project
This project is a collaboration led by the Oslo University Hospital, Department of Cellular Therapy. Project partners include Oslo Cancer Cluster, Sintef, and Thermo Fisher Scientific. The focus is on improving CAR T-cell therapy. This is a treatment where a patient’s T cells are taken and changed before they are put back into the patient so they can better attack cancer cells.

💠APIM Therapeutics
This company is a biotech spin-off from the NTNU - Norges teknisk-naturvitenskapelige universitet. Their main drug, ATX-101, is made to target a weak point in cancer cells, making them less able to deal with stress and avoid being killed by treatments.
This drug has been tested in patients with ovarian cancer (phase Ib) and sarcoma (phase II). It has also been tested in two other ways:

• On animals with cancer: They found that ATX-101 helps other cancer drugs work better on both solid tumors and blood cancers.
• On lab samples from patients: They took bone marrow samples from people with a type of blood cancer called myeloma and found that ATX-101 was very effective at killing those cancer cells in the lab.

Thank you for joining our awareness series🍂 🧬
Stay tuned for more insights into different cancer types every Monday and Wednesday this month.

10/09/2025

In today's awareness series, we want to spread awareness of gynecological cancer. The five main types are cervical, ovarian, uterine, vaginal, and vulvar cancer.

We want to highlight the great work of the Cancer Registry of Norway (Kreftregisteret), which operates CervicalScreen Norway.

This national program aims to:
- Reduce the number of cases and deaths from cervical cancer.
- Provide advice and information to the authorities and the public on preventive measures.

Norwegian health authorities recommend that all women between the ages of 25 and 69 have an HPV test every 5 years.

We also want to highlight the great work of Line Bjørge, medical director in Gynecologic oncology at Helse Bergen Hf and professor in Obstetrics and Gynecology and associated investigator at Center for Cancer Biomarkers (CCBIO) at University of Bergen (Universitetet i Bergen)

Thank you for joining our awareness series 🍂 🧬.
Stay tuned for more insights into different cancer types every Monday and Wednesday this month.

08/09/2025

Today, we're raising awareness for prostate cancer, the most common cancer among men.

We want to highlight the vital work of the Centre for Prostate Cancer (CPC) at Oslo universitetssykehus(OUS). As Norway's largest urology department, it utilizes clinical information and biological samples to conduct research that benefits patients.

The Prostate Cancer Research Group works to gain more knowledge about the causes and development of prostate cancer, which can lead to better diagnostics and treatment.

Their work focuses on a few key areas:
• Clinical Research: Studying patient outcomes and quality of life after treatments, as well as developing new diagnostic methods.
• Translational Research: Finding and confirming new biomarkers in tumor tissue, blood, and urine.

This effort is focused on providing more personalized treatment for patients. The goal is to reduce overdiagnosis and over-treatment of the disease while also improving diagnosis and care for those with high-risk prostate cancer.

Thank you for joining our awareness series 🍂 🧬. Stay tuned for more insights into different cancer types every Monday and Wednesday this month.

03/09/2025

💠 This Wednesday, our focus is on a group of young heroes:
children fighting cancer 👊.

Childhood cancer is a reality for too many families, encompassing various diseases like leukemia, brain tumors, and lymphomas. In Norway, it's the leading cause of death by disease for children between 1 and 14.

We're incredibly proud of the work being done by our members in this critical area. We want to first acknowledge Barnekreftforeningen for their tireless efforts in supporting these young patients and their families. Barnekreftforeningen plays a crucial role in advancing research by providing annual funds for childhood cancer research. This funding enabled the creation of The National Childhood Cancer Biobank in 2017.

We also want to shine a light on one of our member companies, Hemispherian. Hemispherian is an innovative pre-clinical pharmaceutical company. It focuses on developing a promising new class of small-molecule drugs, with its lead compound being GLIX1. This drug is specifically designed to combat glioblastoma, a deadly form of brain cancer and a major cause of death by disease in children.

Hemispherian's approach is unique because its GLIX1 compound is designed to find and attack a specific enzyme inside cancer cells. This causes cancer cells to die with minimal impact on healthy tissue. This precise mechanism is crucial for treating children.
For more information: https://www.hemispherian.com/

Thank you for joining our awareness series 🍂 🧬 . Stay tuned for more insights into different cancer types every Monday and Wednesday this month.